Department of Clinical Medicine, Renal Research Group, University of Bergen, Bergen, Norway; Department of Medicine, Haukeland University Hospital, Bergen, Norway.
Am J Kidney Dis. 2013 Nov;62(5):883-90. doi: 10.1053/j.ajkd.2013.04.019. Epub 2013 Jun 21.
Immunoglobulin A nephropathy (IgAN) is the most common glomerulonephritis globally. Few studies have investigated mortality in patients with IgAN compared with the age- and sex-adjusted general population.
Cohort study with record linkage between the Norwegian Kidney Biopsy Registry, Norwegian Cause of Death Registry, and Norwegian Renal Registry.
SETTING & PARTICIPANTS: 633 patients diagnosed with IgAN in 1988-2004.
Estimated glomerular filtration rate (eGFR), age, and sex.
Deaths and causes of death before and after the onset of end-stage renal disease through 2008.
Mean follow-up was 11.8 (range, 0-20.8) years. During the observation period, the observed number of deaths was 80 and the expected number was 42.1, resulting in a standardized mortality ratio (SMR) of 1.9 (95% CI, 1.5-2.4). Risk stratification based on initial eGFR showed that SMR was 1.0 (95% CI, 0.6-1.6) if eGFR was ≥60 mL/min/1.73 m(2), 1.9 (95% CI, 1.3-2.8) if eGFR was 30-60 mL/min/1.73 m(2), and 3.6 (95% CI, 2.6-5.0) in patients with eGFR <30 mL/min/1.73 m(2). Renal replacement therapy (RRT) was initiated in 146 patients and 35 of the 80 deaths occurred after the start of RRT. The age- and sex-adjusted SMR was not increased significantly in the pre-RRT period (1.3; 95% CI, 1.0-1.7), but was increased after initiation of RRT (4.9; 95% CI, 3.5-7.0). The most common cause of death was cardiovascular disease, accounting for 45% of all deaths.
Treatment during follow-up is not known.
Mortality in patients with IgAN was twice the expected rate, but not significantly increased before RRT. The risk of end-stage renal disease was substantially higher than risk of death.
免疫球蛋白 A 肾病(IgAN)是全球最常见的肾小球肾炎。与年龄和性别相匹配的普通人群相比,很少有研究调查 IgAN 患者的死亡率。
在挪威肾脏活检登记处、挪威死因登记处和挪威肾脏登记处之间进行记录链接的队列研究。
1988-2004 年诊断为 IgAN 的 633 名患者。
估计肾小球滤过率(eGFR)、年龄和性别。
平均随访时间为 11.8 年(0-20.8 年)。在观察期间,观察到 80 例死亡,预期死亡人数为 42.1 例,标准化死亡率比(SMR)为 1.9(95%CI,1.5-2.4)。基于初始 eGFR 的风险分层显示,如果 eGFR≥60mL/min/1.73m2,SMR 为 1.0(95%CI,0.6-1.6);如果 eGFR 为 30-60mL/min/1.73m2,SMR 为 1.9(95%CI,1.3-2.8);如果 eGFR<30mL/min/1.73m2,SMR 为 3.6(95%CI,2.6-5.0)。146 名患者开始接受肾脏替代治疗(RRT),80 例死亡中有 35 例发生在 RRT 开始后。在 RRT 前,年龄和性别调整后的 SMR 没有显著增加(1.3;95%CI,1.0-1.7),但在开始 RRT 后增加(4.9;95%CI,3.5-7.0)。最常见的死亡原因是心血管疾病,占所有死亡人数的 45%。
随访期间的治疗情况未知。
IgAN 患者的死亡率是预期的两倍,但在开始 RRT 之前并未显著增加。终末期肾病的风险明显高于死亡风险。